Emerging evidence is demonstrating the therapeutic benefit of IRAK-4 inhibition in B-cell lymphomas, along with possibly reversing BTK inhibitor resistance. This evidence concerns the gene IRAK4 and B-cell non-Hodgkin lymphoma.